title: Use of the methylxanthine derivative A802715 in transplantation immunology: II. In vivo experiments.
abstract: BACKGROUND
  We have previously demonstrated in vitro that the methylxanthine derivative A802715 suppresses the cyclosporine (CsA)-resistant "signal two"-dependent pathway of T cell activation and hence acts synergistically with CsA. Here, this synergism was further investigated in vivo in rats.
  
  
  METHODS
  Primary cardiac allografts were placed in the neck, and secondary grafts were transplanted intra-abdominally. A802715 was given orally for 30 days or by continuous intravenous infusion via a mini-osmotic pump for 2 weeks. CsA was given orally for up to 30 days. T cell responses were examined in vitro using mixed lymphocyte reaction, concanavalin A whole blood, and cell-mediated lympholysis assays.
  
  
  RESULTS
  In a major histocompatibility complex incompatible WKAH-->PVG combination, neither oral CsA (7.5 mg/kg/day) nor oral A802715 (100 mg/kg/day) was able to prolong graft survival. However, a combination of both drugs, given at the same dose, sustained graft survival during treatment. A similar synergism was not obtained with pentoxifylline, another methylxanthine derivative. The synergism between A802715 and CsA could be further increased by using a continuous intravenous infusion of A802715, since (1) lower doses of A802715 (20 mg/kg/day) and CsA (5 mg/kg/day) could be used, and (2) six of seven grafts survived permanently. In a major histocompatibility complex compatible Wag/Rij-->R/A combination, similar synergistic effects and permanent graft survival could also be obtained by oral A802715 (100 mg/kg/day) in combination with a low dose of CsA (2.5 mg/kg/day). In both strain combinations, long-term survivors accepted donor-type but rejected third-party second grafts in the absence of immunosuppression. This specific tolerance was not related to clonal deletion nor anergy, as recipient lymphocytes proliferated normally in the anti-donor mixed lymphocyte reaction. Instead, a defect in generating specific cytotoxic T lymphocytes was involved.
  
  
  CONCLUSIONS
  A802715 synergizes with CsA in vivo to induce specific transplantation tolerance and hence should be considered as a promising new immunosuppressant.
authors.affiliation: Department of Pharmacology, University of Leuven, Belgium.
authors.forename: Y
authors.initials: Y
authors.lastname: Lin
authors.forename: C
authors.initials: C
authors.lastname: Segers
authors.forename: D
authors.initials: D
authors.lastname: Mikhalsky
authors.forename: T B
authors.initials: TB
authors.lastname: Tjandra-Maga
authors.forename: M
authors.initials: M
authors.lastname: Schönharting
authors.forename: M
authors.initials: M
authors.lastname: Waer
mesh_terms: D000284:Administration, Oral; D000818:Animals; D016572:Cyclosporine / Q000627:therapeutic use*; D004357:Drug Synergism; D006084:Graft Rejection / Q000517:prevention & control; D016027:Heart Transplantation; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D010431:Pentoxifylline / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D014970:Xanthines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D014970:Xanthines; C078398:A 802715; D016572:Cyclosporine; D010431:Pentoxifylline